News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Deals
Sanofi-Aventis (France) Prepares to Raise Genzyme Corporation Bid as GlaxoSmithKline Denies Plans to Step in as Rival Bidder
September 7, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
PARIS, Sept 7 (Reuters) - GlaxoSmithKline (GSK.L) will not step in as a rival bidder for U.S. biotech Genzyme (GENZ.O) and take on Sanofi-Aventis (SASY.PA), the British drugmaker's head of research and development told a French newspaper.
Twitter
LinkedIn
Facebook
Email
Print
Mergers & acquisitions
Europe
Sanofi
GSK
MORE ON THIS TOPIC
Deals
Novo notches up to $1.4B pact with Orbis to develop oral macrocycle cardiometabolic drugs
September 17, 2026
·
2 min read
·
Michael Gibney
Deals
Fed rate hike won’t hold biotech down despite climbing capital costs
September 17, 2026
·
2 min read
·
Annalee Armstrong
Neuroscience
Novartis drops $125M for Sironax’s tech to cross blood-brain barrier
September 17, 2026
·
2 min read
·
Tristan Manalac
Immunology and inflammation
Roche bets up to $1B to advance next-gen bispecifics with Dualitas
September 17, 2026
·
1 min read
·
Tristan Manalac